Utilizing a ‘network’ analysis of proteins, Visterra’s innovative technology platform enables a more in depth structural understanding of proteins to identify unique target epitopes and guide the design of novel drugs that specifically target these epitopes to effectively combat disease.
Visterra’s primary focus is the application of its technology to infectious disease, and its most advanced product in development is a broad spectrum antibody for influenza. Visterra was founded by MIT Professor Ram Sasisekharan and Polaris partner Alan Crane.
One of the key success criteria for any young company is in its ability to establish a network of cross-functional industry experts, which mirrors what larger companies have in house, to help guide the translation of innovative science to breakthrough products. Visterra has benefited significantly from Polaris’ access to this network and most importantly, its proactive commitment to connect us with the right experts at the right time. I believe a large part of Polaris’ success is their focus on matching innovative scientific platforms with experienced and passionate teams. I have experienced this first hand at Momenta and now at Visterra.
- Steven Brugger, CEO : Visterra
One Kendall Square, Suite B3301, Cambridge, MA, 02139
Tel: 617-498-1070
www.visterrainc.com